Clinical Trial Update: Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma [Phase 1]

View source ↗

Summary

This is a Phase 1 trial evaluating low-dose radiotherapy plus tislelizumab in combination with afatinib as neoadjuvant therapy for surgically resectable head an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Afatinib (afatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: West China Hospital | Conditions: Head and Neck Cancer | Phase 1 | Status: COMPLETED